Clinical Trial Update: Treat Malignant Ascites Caused by Gastrointestinal or Ovarian Cancer With M701 Bispecific Antibody [Phase 2]

View source ↗

Summary

Phase 2 trial update of M701 bispecific antibody for malignant ascites in gastrointestinal or ovarian cancer; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Cancer
• Ovarian Cancer

Drugs mentioned

• M701 Bispecific Antibody (M701)

Snippet

Sponsor: Wuhan YZY Biopharma Co., Ltd. | Conditions: Malignant Ascites | Phase 2 | Status: COMPLETED